AstraZeneca : 2022 Sustainability Highlights presentation

2022 Sustainability Highlights

Conference call for investors and analysts

22 March 2023

Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

2

Sustainability at AstraZeneca

Pam Cheng

E X E C U T I V E V I C E P R E S I D E N T, G L O B A L

O P E R AT I O N S , I N F O R M AT I O N T EC H N O L O G Y A N D C H I E F S U S TA I N A B I L I T Y O F F I C E R

3	March 2023

Sustainability Governance at AstraZeneca

Embedding sustainability in everything we do to create value beyond the impact of our medicines

Leif Johansson

Non-Executive Chair of the Board

Pascal Soriot

Executive Director and Chief Executive Officer

BOD

BOD

SET

Board of Directors (BOD)

Nazneen Rahman	BOD

Non-Executive Director of the Board

and Chair of the Sustainability BSC

Committee

BOD

Marcus Wallenberg

Non-Executive Director of the Board BSC

Senior Executive Team (SET)

Pam Cheng

SET

Executive Vice President,

Global Operations,

Information Technology and

Chief Sustainability Officer

Sheri McCoy

Chief Human Resources

Officer, Chief Compliance Officer

and General Counsel

Andreas RummeltSET

Non-Executive Director of the Board

Jeff Pott

Chief Human Resources

Officer, Chief Compliance Officer

and General Counsel

BOD

BSC

BOD

BSC

SET

BOD Board of Directors

SET Senior Executive Team

BSC Board Sustainability Committee

4	March 2023

Industry-leading efforts in Sustainability

Building a sustainable future for people, society and the planet

Sustainability Ratings

Equitable access

Affordability and pricing

Health system resilience

Sustainability

at AstraZeneca

Ethical business culture

Inclusion and diversity

Workforce safety and health

Ambition Zero

Carbon

Product

sustainability

Natural resources

Our three interconnected sustainability priorities

are underpinned by nine focus areas

3rd overall

up from 7th in 2020

Bloomberg Gender-

Equity Index constituent for

5th consecutive year

A for Climate Change and Water Security

World & Europe

constituent

AA MSCI ESG rating

maintained since 2014

decreasing ESG Risk

Rating since 2019

5	March 2023